Literature DB >> 11244689

[Hypertrophic pachymeningitis. A review of the histories of two cases and pathological relationship with the Tolosa-Hunt syndrome and the orbital pseudotumor].

J Bosch1, A Ortega-Aznar, M Tintoré, J Río, R Ferreira, E Rubio, A Rovira, S Abilleira, A Mauleón, X Montalbán, M Boada, A Codina.   

Abstract

INTRODUCTION: Hypertrophic pachymeningitis is an infrequent condition which starts with a thickening of the dura mater and whose pathogenesis is unknown. We present two new cases of unknown aetiology. CLINICAL CASE: Case 1. A 53 year old man complained of occipital headache, tinnitus and deafness since February 1981. In October 1981 he was admitted to hospital with a worse headache, perio-orbital pain, dysgeusia and ipsilateral peripheral facial palsy. In December he had generalized tonic-clonic seizures and paralysis of the VII and XI right cranial nerves and IX, X and XII left cranial nerves. In February 1982 he developed right trigeminal neuralgia. He was readmitted in November 1983 with continuous headache, vomiting and a behavior disorder. On CT there was marked attenuation of the posterior dura mater, which the neurosurgical department considered unsuitable for biopsy. He died in March 1985. On necropsy there was hypertrophic pachymeningitis. Case 2. A 62 year old patient consulted in November 1995 complaining of right hypoacusia for the past six months, progressively accompanied by ipsilateral paralysis of the II, IV, VI, VII and VIII cranial nerves but with no other alterations on physical examination. Analytical and serological investigations were normal. Cranial MR showed an extraparenchymatous infiltrating lesion in the middle cranial fossa. Biopsy was decided on when no clinical improvement was seen with corticosteroid treatment. The pathologist reported hypertrophic pachymeningitis. Treatment was started with cyclophosphamide in monthly doses and the condition has remained stable to date.
CONCLUSION: With these two cases we wish to establish a pathogenic relation between the Tolosa-Hunt syndrome and orbital pseudotumor and show the role played by immunosuppressive treatment in the control of hypertrophic pachymeningitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11244689

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

1.  Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia.

Authors:  Laurent Auboire; Jonathan Boutemy; Jean Marc Constans; Thomas Le Gallou; Philippe Busson; Boris Bienvenu
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

2.  Inflammatory myofibroblastic tumor of the orbit with associated enhancement of the meninges and multiple cranial nerves.

Authors:  A M McKinney; J Short; L Lucato; K SantaCruz; Z McKinney; Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

Review 3.  An approach to the patient with painful ophthalmoplegia, with a focus on Tolosa-Hunt syndrome.

Authors:  Jonathan P Gladstone
Journal:  Curr Pain Headache Rep       Date:  2007-08

4.  The evaluation of ICHD-3 beta diagnostic criteria for Tolosa-Hunt syndrome: a study of 22 cases of Tolosa-Hunt syndrome.

Authors:  Rui Hao; Yanjin He; Hong Zhang; Wei Zhang; Xiaorong Li; Yifeng Ke
Journal:  Neurol Sci       Date:  2015-03-04       Impact factor: 3.307

Review 5.  Tolosa-Hunt Syndrome: A Review of Diagnostic Criteria and Unresolved Issues.

Authors:  Paromita Dutta; Kamlesh Anand
Journal:  J Curr Ophthalmol       Date:  2021-07-05

Review 6.  Painful ophthalmoplegia: overview with a focus on Tolosa-Hunt syndrome.

Authors:  Jonathan P Gladstone; David W Dodick
Journal:  Curr Pain Headache Rep       Date:  2004-08

7.  Hypertrophic cranial pachymeningitis and skull base osteomyelitis by pseudomonas aeruginosa: case report and review of the literature.

Authors:  Ana Rita Caldas; Mariana Brandao; Filipe Seguro Paula; Elsa Castro; Fatima Farinha; Antonio Marinho
Journal:  J Clin Med Res       Date:  2012-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.